| __timestamp | Incyte Corporation | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 3004000 | 179279000 |
| Thursday, January 1, 2015 | 26972000 | 186359000 |
| Friday, January 1, 2016 | 58187000 | 171785000 |
| Sunday, January 1, 2017 | 79479000 | 208136000 |
| Monday, January 1, 2018 | 94123000 | 198405000 |
| Tuesday, January 1, 2019 | 114249000 | 224169000 |
| Wednesday, January 1, 2020 | 131328000 | 245044000 |
| Friday, January 1, 2021 | 150991000 | 252314000 |
| Saturday, January 1, 2022 | 206997000 | 268225000 |
| Sunday, January 1, 2023 | 255000000 | 304629000 |
| Monday, January 1, 2024 | 312068000 | 324203000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. This chart offers a fascinating glimpse into the cost of revenue trends for Incyte Corporation and Taro Pharmaceutical Industries Ltd. over the past decade. From 2014 to 2023, Taro consistently outpaced Incyte, with its cost of revenue peaking at approximately 324 million in 2024, a 10% increase from the previous year. Incyte, on the other hand, saw a dramatic rise, with costs surging by over 8,300% from 2014 to 2023, reaching around 255 million. This stark contrast highlights Taro's steady growth and Incyte's rapid expansion. However, 2024 data for Incyte remains elusive, leaving room for speculation. As these companies navigate the complexities of the pharmaceutical landscape, their financial strategies will undoubtedly continue to shape their competitive edge.
Eli Lilly and Company vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Pfizer Inc. and Incyte Corporation
Cost of Revenue: Key Insights for Zoetis Inc. and Taro Pharmaceutical Industries Ltd.
Cost of Revenue: Key Insights for Biogen Inc. and Incyte Corporation
Cost of Revenue Trends: Incyte Corporation vs Lantheus Holdings, Inc.
Cost of Revenue Comparison: Incyte Corporation vs Alkermes plc
Research and Development Expenses Breakdown: Incyte Corporation vs Taro Pharmaceutical Industries Ltd.
Cost of Revenue Trends: Dr. Reddy's Laboratories Limited vs Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Catalent, Inc. and Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: HUTCHMED (China) Limited and Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Mesoblast Limited and Taro Pharmaceutical Industries Ltd.
Cost of Revenue Trends: Taro Pharmaceutical Industries Ltd. vs Evotec SE